The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 8, 2008, Pages 407-414

  Leitner, J M ^a   Mayr, F B ^a   Spiel, A O ^a   Firbas, C ^a   Savulsky, C ^b   Mis, R ^b   Corrado, M E ^c   Jilma, Bernard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Gp Pharm SA   (Spain)

^c Cross Research SA   (Switzerland)

Author keywords

Castration; LHRH analogue; Micro spheres; Testosterone

Indexed keywords

LEUPRORELIN; LUTRATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; HORMONE DETERMINATION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIBIDO DISORDER; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PILOT STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; TESTOSTERONE BLOOD LEVEL;

EID: 48749128411     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46407     Document Type: Article

References (15)

1. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5mg La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002; 168: 1199-1203.
2. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006; 175: 533-536.
3. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R 3rd, Murphy GP. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol. 1995; 59: 246-250.
4. Morales A. Androgen replacement therapy and prostate safety. Eur Urol. 2002; 41: 113-120.
5. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997; 28: 43-70.
6. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002; 41: 485-504.
7. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994; 48: 930-967.
8. Raina R, Pahalajani G, Agarwal A, Zippe C. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian J Androl. 2007; 9: 253-258.
9. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003; 170: 2348-2351.
10. Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol. 1990; 143: 68-71.
11. Slager J, Domb AJ. Hetero-stereocomplexes of D-poly (lactic acid) and the LHRH analogue leuprolide. Application in controlled release. Eur J Pharm Biopharm. 2004; 58: 461-469.
12. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992; 75: 1092-1098.
13. Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int. 1998; 60 (Suppl 1): 9-17.
14. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci. 2003; 997: 229-239.
15. Yasukawa K, Sawamura D, Sugawara H, Kato N. Leuprorelin acetate granulomas: case reports and review of the literature. Br J Dermatol. 2005; 152: 1045-1047.